{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:52:41Z","timestamp":1791075161862,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"DOI":"10.1038\/s41380-026-03918-4","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:37:40Z","timestamp":1791027460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychedelics and disorders of consciousness: a new frontier in neurotherapeutics"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-074X","authenticated-orcid":false,"given":"Xiubo","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3415-5612","authenticated-orcid":false,"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"3918_CR1","doi-asserted-by":"publisher","DOI":"10.34133\/research.0495","volume":"7","author":"MY Zhang","year":"2024","unstructured":"Zhang MY, Wang YB, Gao TM, Wang XH. Psychedelics and consciousness: expanding the horizons of mind and therapy. Research. 2024;7:0495.","journal-title":"Research"},{"key":"3918_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pmr.2023.06.011","volume":"35","author":"K Golden","year":"2024","unstructured":"Golden K, Bodien YG, Giacino JT. Disorders of consciousness classification and taxonomy. Phys Med Rehabil Clin N Am. 2024;35:15\u201333.","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"3918_CR3","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1093\/brain\/awx163","volume":"140","author":"S Chennu","year":"2017","unstructured":"Chennu S, Annen J, Wannez S, Thibaut A, Chatelle C, Cassoi H, et al. Brain networks predict metabolism, diagnosis and prognosis at the bedside in disorders of consciousness. Brain. 2017;140:2120\u201332.","journal-title":"Brain"},{"key":"3918_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jnnp-2015-310958","volume":"87","author":"D Kondziella","year":"2016","unstructured":"Kondziella D, Friberg CK, Frokjaer VG, Fabricius M, Moller K. Preserved consciousness in vegetative and minimal conscious states: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016;87:485\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3918_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(14)60042-8","volume":"384","author":"J Stender","year":"2014","unstructured":"Stender J, Gosseries O, Bruno MA, Charland-Verville V, Vanhaudenhuyse A, Demertzi A, et al. Diagnostic precision of PET imaging and functional MRI in disorders of consciousness: a clinical validation study. Lancet. 2014;384:514\u201322.","journal-title":"Lancet"},{"key":"3918_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s12264-024-01341-9","volume":"41","author":"H Zhai","year":"2025","unstructured":"Zhai H, Wang Y, Wang X. Psychoactive substances: transforming the paradigm for treating mental health disorders in the post-pandemic era. Neurosci Bull. 2025;41:536\u20138.","journal-title":"Neurosci Bull"},{"key":"3918_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","volume":"8","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20.","journal-title":"Front Hum Neurosci"},{"key":"3918_CR8","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA. 2016;113:4853\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3918_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuroimage.2019.05.060","volume":"199","author":"LD Lord","year":"2019","unstructured":"Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, et al. Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. Neuroimage. 2019;199:127\u201342.","journal-title":"Neuroimage"},{"key":"3918_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.biopsych.2019.12.027","volume":"88","author":"KH Preller","year":"2020","unstructured":"Preller KH, Duerler P, Burt JB, Ji JL, Adkinson B, St\u00e4mpfli P, et al. Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry. 2020;88:197\u2013207.","journal-title":"Biol Psychiatry"},{"key":"3918_CR11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082","volume":"7","author":"KH Preller","year":"2018","unstructured":"Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stampfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7:e35082.","journal-title":"Elife"},{"key":"3918_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","volume":"14","author":"LP Cameron","year":"2023","unstructured":"Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci. 2023;14:351\u20138.","journal-title":"ACS Chem Neurosci"},{"key":"3918_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611\u201324.","journal-title":"Nat Rev Neurosci"},{"key":"3918_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2022.119434","volume":"260","author":"A Gaddis","year":"2022","unstructured":"Gaddis A, Lidstone DE, Nebel MB, Griffiths RR, Mostofsky SH, Mejia AF, et al. Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity. Neuroimage. 2022;260:119434.","journal-title":"Neuroimage"},{"key":"3918_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71:316\u201344.","journal-title":"Pharmacol Rev"},{"key":"3918_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1212\/01.WNL.0000150883.10285.44","volume":"64","author":"ND Schiff","year":"2005","unstructured":"Schiff ND, Rodriguez-Moreno D, Kamal A, Kim KHS, Giacino JT, Plum F, et al. fMRI reveals large-scale network activation in minimally conscious patients. Neurology. 2005;64:514\u201323.","journal-title":"Neurology"},{"key":"3918_CR17","doi-asserted-by":"publisher","first-page":"niz003","DOI":"10.1093\/nc\/niz003","volume":"2019","author":"G Scott","year":"2019","unstructured":"Scott G, Carhart-Harris RL. Psychedelics as a treatment for disorders of consciousness. Neurosci Conscious. 2019;2019:niz003.","journal-title":"Neurosci Conscious"},{"key":"3918_CR18","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u201344.","journal-title":"Neuron"},{"key":"3918_CR19","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"3918_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020705118","volume":"118","author":"D De Gregorio","year":"2021","unstructured":"De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, et al. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci USA. 2021;118:e2020705118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3918_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.727117","volume":"12","author":"MV Vargas","year":"2021","unstructured":"Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and other psychoplastogens for treating mental illness. Front Psychiatry. 2021;12:727117.","journal-title":"Front Psychiatry"},{"key":"3918_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700\u20136.","journal-title":"Science"},{"key":"3918_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/02698811211026454","volume":"36","author":"DEW McCulloch","year":"2022","unstructured":"McCulloch DEW, Madsen MK, Stenb\u00e6k DS, Kristiansen S, Ozenne B, Jensen PS, et al. Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol. 2022;36:74\u201384.","journal-title":"J Psychopharmacol"},{"key":"3918_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2023.120097","volume":"273","author":"R Dai","year":"2023","unstructured":"Dai R, Larkin TE, Huang Z, Tarnal V, Picton P, Vlisides PE, et al. Classical and non-classical psychedelic drugs induce common network changes in human cortex. Neuroimage. 2023;273:120097.","journal-title":"Neuroimage"},{"key":"3918_CR25","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1046\/j.1471-4159.2003.01921.x","volume":"86","author":"DM Kurrasch-Orbaugh","year":"2003","unstructured":"Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE. A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem. 2003;86:980\u201391.","journal-title":"J Neurochem"},{"key":"3918_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2022.104161","volume":"52","author":"ND Schiff","year":"2023","unstructured":"Schiff ND. Mesocircuit mechanisms in the diagnosis and treatment of disorders of consciousness. Presse Med. 2023;52:104161.","journal-title":"Presse Med"},{"key":"3918_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0300-9572(98)00133-6","volume":"39","author":"VA Akulinin","year":"1998","unstructured":"Akulinin VA, Belichenko PV, Dahlstrom A. Quantitative analysis of synaptophysin immunoreactivity in human neocortex after cardiac arrest: confocal laser scanning microscopy study. Resuscitation. 1998;39:207\u201313.","journal-title":"Resuscitation"},{"key":"3918_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/brain\/123.7.1327","volume":"123","author":"JH Adams","year":"2000","unstructured":"Adams JH, Graham DI, Jennett B. The neuropathology of the vegetative state after an acute brain insult. Brain. 2000;123:1327\u201338.","journal-title":"Brain"},{"key":"3918_CR29","doi-asserted-by":"publisher","first-page":"13513","DOI":"10.1523\/JNEUROSCI.1665-10.2010","volume":"30","author":"CL Schmid","year":"2010","unstructured":"Schmid CL, Bohn LM. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2\/Src\/Akt signaling complex in vivo. J Neurosci. 2010;30:13513\u201324.","journal-title":"J Neurosci"},{"key":"3918_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT(2A) receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14:8221.","journal-title":"Nat Commun"},{"key":"3918_CR31","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"Moliner R","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"3918_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110622","volume":"279","author":"M Fryc","year":"2025","unstructured":"Fryc M, Kluzik D, Czopek A, Jonczyk J, Zagorska A. Serotonin 2A (5-HT(2A)) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases. Neuropharmacology. 2025;279:110622.","journal-title":"Neuropharmacology"},{"key":"3918_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0165-0173(02)00181-9","volume":"39","author":"YD Van der Werf","year":"2002","unstructured":"Van der Werf YD, Witter MP, Groenewegen HJ. The intralaminar and midline nuclei of the thalamus. anatomical and functional evidence for participation in processes of arousal and awareness. Brain Res Brain Res Rev. 2002;39:107\u201340.","journal-title":"Brain Res Brain Res Rev"},{"key":"3918_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S0140-6736(06)68508-5","volume":"367","author":"JL Bernat","year":"2006","unstructured":"Bernat JL. Chronic disorders of consciousness. Lancet. 2006;367:1181\u201392.","journal-title":"Lancet"},{"key":"3918_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/jcbfm.2014.169","volume":"35","author":"J Stender","year":"2015","unstructured":"Stender J, Kupers R, Rodell A, Thibaut A, Chatelle C, Bruno MA, et al. Quantitative rates of brain glucose metabolism distinguish minimally conscious from vegetative state patients. J Cereb Blood Flow Metab. 2015;35:58\u201365.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3918_CR36","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959\u201364.","journal-title":"Science"},{"key":"3918_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91\u201395.","journal-title":"Nature"},{"key":"3918_CR38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/02698811231179801","volume":"37","author":"JN Bonnieux","year":"2023","unstructured":"Bonnieux JN, VanderZwaag B, Premji Z, Garcia-Romeu A, Garcia-Barrera MA. Psilocybin\u2019s effects on cognition and creativity: a scoping review. J Psychopharmacol. 2023;37:635\u201348.","journal-title":"J Psychopharmacol"},{"key":"3918_CR39","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1124\/pharmrev.121.000508","volume":"74","author":"D Stoliker","year":"2022","unstructured":"Stoliker D, Egan GF, Friston KJ, Razi A. Neural mechanisms and psychology of psychedelic ego dissolution. Pharmacol Rev. 2022;74:876\u2013917.","journal-title":"Pharmacol Rev"},{"key":"3918_CR40","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/ana.24779","volume":"80","author":"S Casarotto","year":"2016","unstructured":"Casarotto S, Comanducci A, Rosanova M, Sarasso S, Fecchio M, Napolitani M, et al. Stratification of unresponsive patients by an independently validated index of brain complexity. Ann Neurol. 2016;80:718\u201329.","journal-title":"Ann Neurol"},{"key":"3918_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202511780","volume":"13","author":"NLN Alnagger","year":"2026","unstructured":"Alnagger NLN, Cardone P, Martial C, Perl YS, Mindlin I, Sitt JD, et al. A virtual clinical trial of psychedelics to treat patients with disorders of consciousness. Adv Sci. 2026;13:e11780.","journal-title":"Adv Sci"},{"key":"3918_CR42","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1212\/WNL.0000000000005928","volume":"91","author":"JT Giacino","year":"2018","unstructured":"Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. Comprehensive systematic review update summary: disorders of consciousness: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology; the American congress of rehabilitation medicine; and the national institute on disability, independent living, and rehabilitation research. Neurology. 2018;91:461\u201370.","journal-title":"Neurology"},{"key":"3918_CR43","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1474-4422(04)00852-X","volume":"3","author":"S Laureys","year":"2004","unstructured":"Laureys S, Owen AM, Schiff ND. Brain function in coma, vegetative state, and related disorders. Lancet Neurol. 2004;3:537\u201346.","journal-title":"Lancet Neurol"},{"key":"3918_CR44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.neuroimage.2011.12.041","volume":"61","author":"S Laureys","year":"2012","unstructured":"Laureys S, Schiff ND. Coma and consciousness: paradigms (re)framed by neuroimaging. Neuroimage. 2012;61:478\u201391.","journal-title":"Neuroimage"},{"key":"3918_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.102071","volume":"24","author":"B Cao","year":"2019","unstructured":"Cao B, Chen Y, Yu R, Chen L, Chen P, Weng Y, et al. Abnormal dynamic properties of functional connectivity in disorders of consciousness. Neuroimage Clin. 2019;24:102071.","journal-title":"Neuroimage Clin"},{"key":"3918_CR46","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.clinph.2025.02.264","volume":"173","author":"P Cardone","year":"2025","unstructured":"Cardone P, Nunez P, Alnagger NLN, Martial C, van der Lande GJM, Sandell R, et al. Psilocybin for disorders of consciousness: a case-report study. Clin Neurophysiol. 2025;173:181\u20139.","journal-title":"Clin Neurophysiol"},{"key":"3918_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"3918_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","volume":"26","author":"JJ Gattuso","year":"2023","unstructured":"Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, et al. Default mode network modulation by psychedelics: a systematic review. Int J Neuropsychoph. 2023;26:155\u201388.","journal-title":"Int J Neuropsychoph"},{"key":"3918_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/nc\/niae025","volume":"2024","author":"P Cardone","year":"2024","unstructured":"Cardone P, Alnagger N, Annen J, Bicego A, Gosseries O, Martial C. Psychedelics and disorders of consciousness: the current landscape and the path forward. Neurosci Conscious. 2024;2024:niae025.","journal-title":"Neurosci Conscious"},{"key":"3918_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1386321","volume":"15","author":"Z Yu","year":"2024","unstructured":"Yu Z, Burback L, Winkler O, Xu L, Dennett L, Vermetten E, et al. Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. Front Psychiatry. 2024;15:1386321.","journal-title":"Front Psychiatry"},{"key":"3918_CR51","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, et al. Increased global functional connectivity correlates with LSD-Induced ego dissolution. Curr Biol. 2016;26:1043\u201350.","journal-title":"Curr Biol"},{"key":"3918_CR52","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1212\/WNL.0000000000005926","volume":"91","author":"JT Giacino","year":"2018","unstructured":"Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, et al. Practice guideline update recommendations summary: disorders of consciousness: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology; the American congress of rehabilitation medicine; and the national institute on disability, independent living, and rehabilitation research. Neurology. 2018;91:450\u201360.","journal-title":"Neurology"},{"key":"3918_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111639","volume":"28","author":"P Cardone","year":"2025","unstructured":"Cardone P, Bonhomme A, Bonhomme V, Lejeune N, Staquet C, Defresne A, et al. A pilot human study using ketamine to treat disorders of consciousness. iScience. 2025;28:111639.","journal-title":"iScience"},{"key":"3918_CR54","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"3918_CR55","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s42003-024-06852-9","volume":"7","author":"I Mindlin","year":"2024","unstructured":"Mindlin I, Herzog R, Belloli L, Manasova D, Monge-Asensio M, Vohryzek J, et al. Whole brain modelling for simulating pharmacological interventions on patients with disorders of consciousness. Commun Biol. 2024;7:1176.","journal-title":"Commun Biol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03918-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03918-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:03:54Z","timestamp":1791072234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03918-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":55,"alternative-id":["3918"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03918-4","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}